Highlights

  • Opthea has reinstated to ASX trading on June 3, 2026, following a strategic review that concluded in December 2025 — the company is pivoting OPT-302 to lymphangioleiomyomatosis (LAM), a rare chronic lung disease primarily affecting women
  • The company holds A$31.2 million in cash as of March 31, 2026, with the 18-month LAM development program (Stages 1-3) estimated to cost approximately A$13.1 million including corporate expenses
  • A proposed name change from Opthea Limited to Ceryvyn Therapeutics Limited has been put to an extraordinary general meeting, reflecting the company's departure from its ophthalmology heritage

 

Opthea Limited (ASX:OPT) fell sharply on its return to ASX trading on June 3, 2026, declining 97.17% to A$0.017. The extent of the fall reflects the accumulated uncertainty that built during the Trading halt period following the company's failed Phase 3 Clinical Trials for wet age-related macular degeneration in late 2024 and early 2025, as well as the fundamental repositioning the company has undergone. Investors who held shares at pre-halt prices were confronted on reinstatement with a materially smaller, strategically transformed company pursuing a new therapeutic indication.

What Led to the Reinstatement

Opthea's previous Business was built around OPT-302, a VEGF-C and VEGF-D inhibitor originally developed as a combination therapy for wet AMD. When the Phase 3 trials did not achieve their primary endpoints, the company entered a period of strategic review to identify what, if any, residual value could be preserved from its significant Investment in OPT-302's clinical and Manufacturing infrastructure. The conclusion of that review — announced in December 2025 — was to redirect OPT-302 toward lymphangioleiomyomatosis.

LAM: The Disease and the Rationale for OPT-302

Lymphangioleiomyomatosis is a rare, chronic lung disease characterised by abnormal smooth muscle cell proliferation in the lungs and lymphatic system. It primarily affects women of childbearing age and is progressive, with no curative treatment currently available. The only approved therapy is an immunosuppressant that does not directly target the underlying VEGF-related biology of the disease and is associated with systemic side effects that lead to treatment discontinuation.

The rationale for OPT-302 in LAM is grounded in the biological mechanism: LAM is characterised by elevated levels of VEGF-C and VEGF-D and pathological activation of VEGFR-3 signalling in lymphatic vessels. OPT-302 is designed to inhibit precisely these two growth factors. If OPT-302 can dampen the lymphatic signalling pathways that drive LAM, the hypothesis is that it could stabilise lung function and slow disease progression through a mechanism not addressed by any currently approved therapy.

Three-Stage Development Plan

The company has outlined a three-stage, 18-month development program. Stage 1, currently underway, focuses on preclinical biology and inhalation studies — specifically evaluating whether OPT-302 can be nebulised for delivery directly to the lung, where LAM's clinical burden is concentrated. Preliminary safety and tolerability work in large animal inhalation studies is ongoing.

Stage 2, contingent on satisfactory Stage 1 outcomes, would involve early clinical studies to assess tolerability and pharmacodynamic evidence of VEGF-C and VEGF-D modulation in humans. Stage 3 would advance to a clinical proof-of-concept study in LAM patients, with endpoints encompassing lung function and lymphatic-related measures. Each stage is gated on predefined scientific, operational, and Capital allocation criteria reviewed by the board.

Cash Position and Use of Funds

With A$31.2 million in cash at March 31, 2026, and an estimated A$13.1 million budgeted for the three-stage program plus corporate expenses over 18 months, Opthea enters the reinstatement period with a materially cushioned Balance Sheet relative to its near-term obligations. The largest single cost component is corporate and administration, estimated at A$5.1 million across the period, followed by the LAM program at approximately A$6.0 million.

The board's capital allocation framework is described as disciplined and stage-gated, with progression between stages conditional on data rather than automatic. This is standard in rare disease Drug Development, where early-stage attrition rates are high and the ability to halt spending before committing to larger clinical trials is a key risk management tool.

Orphan Drug Designation and Commercial Positioning

The company intends to seek orphan drug designation for OPT-302 in LAM at an appropriate time. Orphan designation in the US, EU, Japan, and Australia can unlock market exclusivity for seven to ten years post-approval, reduced or waived regulatory filing fees, accelerated review timelines, and potential tax credits — a commercially meaningful suite of incentives for a rare disease program where the patient population is small but concentrated in specialised treatment centres.

Conclusion

Opthea's return to ASX trading marks the beginning of a new chapter for a company that has undergone one of the more dramatic repositioning exercises among listed Australian biotechs in recent years. The pivot from wet AMD combination therapy to an inhaled LAM program leverages OPT-302's existing mechanism of action, manufacturing infrastructure, and clinical data in a new indication with unmet medical need, orphan drug incentives, and a concentrated patient population. With A$31 million in cash and a staged development plan that calibrates spending to scientific milestones, the company is structured for measured progress rather than rapid burn.